Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation ‐ Normoresponders (MPA 10 mg versus GnRH… compared with gnRH antagonists; GRADE not reported.
2 findings from 1 review
Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes clinical improvement D60 or moref compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found